ENTRY       mmu04933                    Pathway
NAME        AGE-RAGE signaling pathway in diabetic complications - Mus musculus (mouse)
DESCRIPTION Advanced glycation end products (AGEs) are a complex group of compounds produced through the non-enzymatic glycation and oxidation of proteins, lipids and nucleic acids, primarily due to aging and under certain pathologic condition such as huperglycemia. Some of the best chemically characterized AGEs include N-epsilon-carboxy-methyl-lysine (CML), N-epsilon-carboxy-ethyl-lysine (CEL), and Imidazolone. The major receptor for AGEs, known as receptor for advanced glycation end products (RAGE or AGER), belongs to the immunoglobulin superfamily and has been described as a pattern recognition receptor. AGE/RAGE signaling elicits activation of multiple intracellular signal pathways involving NADPH oxidase, protein kinase C, and MAPKs, then resulting in NF-kappaB activity. NF-kappa B promotes the expression of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-alpha and a variety of atherosclerosis-related genes, including VCAM-1, tissue factor, VEGF, and RAGE. In addition, JAK-STAT-mediated and PI3K-Akt-dependent pathways are induced via RAGE, which in turn participate in cell proliferation and apoptosis respectively. Hypoxia-mediated induction of Egr-1 was also shown to require the AGE-RAGE interaction. The results of these signal transductions have been reported to be the possible mechanism that initates diabetic complications.
CLASS       Human Diseases; Endocrine and metabolic disease
PATHWAY_MAP mmu04933  AGE-RAGE signaling pathway in diabetic complications
DBLINKS     GO: 1904603
ORGANISM    Mus musculus (mouse) [GN:mmu]
GENE        21808  Tgfb2; transforming growth factor, beta 2 [KO:K13376]
            21809  Tgfb3; transforming growth factor, beta 3 [KO:K13377]
            21803  Tgfb1; transforming growth factor, beta 1 [KO:K13375]
            21812  Tgfbr1; transforming growth factor, beta receptor I [KO:K04674] [EC:2.7.11.30]
            21813  Tgfbr2; transforming growth factor, beta receptor II [KO:K04388] [EC:2.7.11.30]
            17126  Smad2; SMAD family member 2 [KO:K04500]
            17127  Smad3; SMAD family member 3 [KO:K23605]
            17128  Smad4; SMAD family member 4 [KO:K04501]
            12576  Cdkn1b; cyclin-dependent kinase inhibitor 1B [KO:K06624]
            14268  Fn1; fibronectin 1 [KO:K05717]
            12842  Col1a1; collagen, type I, alpha 1 [KO:K06236]
            12843  Col1a2; collagen, type I, alpha 2 [KO:K06236]
            12825  Col3a1; collagen, type III, alpha 1 [KO:K19720]
            12826  Col4a1; collagen, type IV, alpha 1 [KO:K06237]
            12827  Col4a2; collagen, type IV, alpha 2 [KO:K06237]
            12829  Col4a4; collagen, type IV, alpha 4 [KO:K06237]
            94216  Col4a6; collagen, type IV, alpha 6 [KO:K06237]
            12830  Col4a5; collagen, type IV, alpha 5 [KO:K06237]
            12828  Col4a3; collagen, type IV, alpha 3 [KO:K06237]
            11606  Agt; angiotensinogen (serpin peptidase inhibitor, clade A, member 8) [KO:K09821]
            11607  Agtr1a; angiotensin II receptor, type 1a [KO:K04166]
            11608  Agtr1b; angiotensin II receptor, type 1b [KO:K04166]
            11596  Ager; advanced glycosylation end product-specific receptor [KO:K19722]
            237038  Nox1; NADPH oxidase 1 [KO:K08008]
            13058  Cybb; cytochrome b-245, beta polypeptide [KO:K21421] [EC:1.-.-.-]
            50490  Nox4; NADPH oxidase 4 [KO:K21423] [EC:1.6.3.-]
            18799  Plcd1; phospholipase C, delta 1 [KO:K05857] [EC:3.1.4.11]
            72469  Plcd3; phospholipase C, delta 3 [KO:K05857] [EC:3.1.4.11]
            18802  Plcd4; phospholipase C, delta 4 [KO:K05857] [EC:3.1.4.11]
            18795  Plcb1; phospholipase C, beta 1 [KO:K05858] [EC:3.1.4.11]
            18797  Plcb3; phospholipase C, beta 3 [KO:K05858] [EC:3.1.4.11]
            18798  Plcb4; phospholipase C, beta 4 [KO:K05858] [EC:3.1.4.11]
            18796  Plcb2; phospholipase C, beta 2 [KO:K05858] [EC:3.1.4.11]
            18803  Plcg1; phospholipase C, gamma 1 [KO:K01116] [EC:3.1.4.11]
            234779  Plcg2; phospholipase C, gamma 2 [KO:K05859] [EC:3.1.4.11]
            74055  Plce1; phospholipase C, epsilon 1 [KO:K05860] [EC:3.1.4.11]
            18750  Prkca; protein kinase C, alpha [KO:K02677] [EC:2.7.11.13]
            18751  Prkcb; protein kinase C, beta [KO:K19662] [EC:2.7.11.13]
            18753  Prkcd; protein kinase C, delta [KO:K06068] [EC:2.7.11.13]
            18754  Prkce; protein kinase C, epsilon [KO:K18050] [EC:2.7.11.13]
            18762  Prkcz; protein kinase C, zeta [KO:K18952] [EC:2.7.11.13]
            26413  Mapk1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
            26417  Mapk3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
            16476  Jun; jun proto-oncogene [KO:K04448]
            22339  Vegfa; vascular endothelial growth factor A [KO:K05448]
            22340  Vegfb; vascular endothelial growth factor B [KO:K16858]
            22341  Vegfc; vascular endothelial growth factor C [KO:K05449]
            14205  Vegfd; vascular endothelial growth factor D [KO:K05449]
            20296  Ccl2; chemokine (C-C motif) ligand 2 [KO:K14624]
            20293  Ccl12; chemokine (C-C motif) ligand 12 [KO:K14624]
            18787  Serpine1; serine (or cysteine) peptidase inhibitor, clade E, member 1 [KO:K03982]
            20339  Sele; selectin, endothelial cell [KO:K06494]
            22329  Vcam1; vascular cell adhesion molecule 1 [KO:K06527]
            15894  Icam1; intercellular adhesion molecule 1 [KO:K06490]
            17390  Mmp2; matrix metallopeptidase 2 [KO:K01398] [EC:3.4.24.24]
            16175  Il1a; interleukin 1 alpha [KO:K04383]
            16176  Il1b; interleukin 1 beta [KO:K04519]
            16193  Il6; interleukin 6 [KO:K05405]
            21926  Tnf; tumor necrosis factor [KO:K03156]
            14066  F3; coagulation factor III [KO:K03901]
            13614  Edn1; endothelin 1 [KO:K16366]
            21824  Thbd; thrombomodulin [KO:K03907]
            26416  Mapk14; mitogen-activated protein kinase 14 [KO:K04441] [EC:2.7.11.24]
            19094  Mapk11; mitogen-activated protein kinase 11 [KO:K04441] [EC:2.7.11.24]
            29857  Mapk12; mitogen-activated protein kinase 12 [KO:K04441] [EC:2.7.11.24]
            26415  Mapk13; mitogen-activated protein kinase 13 [KO:K04441] [EC:2.7.11.24]
            19697  Rela; v-rel reticuloendotheliosis viral oncogene homolog A (avian) [KO:K04735]
            18033  Nfkb1; nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 [KO:K02580]
            26419  Mapk8; mitogen-activated protein kinase 8 [KO:K04440] [EC:2.7.11.24]
            26420  Mapk9; mitogen-activated protein kinase 9 [KO:K04440] [EC:2.7.11.24]
            26414  Mapk10; mitogen-activated protein kinase 10 [KO:K04440] [EC:2.7.11.24]
            13367  Diaph1; diaphanous related formin 1 [KO:K05740]
            19353  Rac1; Rac family small GTPase 1 [KO:K04392]
            12540  Cdc42; cell division cycle 42 [KO:K04393]
            15461  Hras; Harvey rat sarcoma virus oncogene [KO:K02833]
            16653  Kras; Kirsten rat sarcoma viral oncogene homolog [KO:K07827]
            18176  Nras; neuroblastoma ras oncogene [KO:K07828]
            18706  Pik3ca; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
            18707  Pik3cd; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
            74769  Pik3cb; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
            18709  Pik3r2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
            18708  Pik3r1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
            18710  Pik3r3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
            11651  Akt1; thymoma viral proto-oncogene 1 [KO:K04456] [EC:2.7.11.1]
            11652  Akt2; thymoma viral proto-oncogene 2 [KO:K04456] [EC:2.7.11.1]
            23797  Akt3; thymoma viral proto-oncogene 3 [KO:K04456] [EC:2.7.11.1]
            18127  Nos3; nitric oxide synthase 3, endothelial cell [KO:K13242] [EC:1.14.13.39]
            56458  Foxo1; forkhead box O1 [KO:K07201]
            12043  Bcl2; B cell leukemia/lymphoma 2 [KO:K02161]
            12028  Bax; BCL2-associated X protein [KO:K02159]
            12367  Casp3; caspase 3 [KO:K02187] [EC:3.4.22.56]
            16452  Jak2; Janus kinase 2 [KO:K04447] [EC:2.7.10.2]
            20848  Stat3; signal transducer and activator of transcription 3 [KO:K04692]
            18712  Pim1; proviral integration site 1 [KO:K04702] [EC:2.7.11.1]
            18018  Nfatc1; nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 [KO:K04446]
            20846  Stat1; signal transducer and activator of transcription 1 [KO:K11220]
            20850  Stat5a; signal transducer and activator of transcription 5A [KO:K11223]
            20851  Stat5b; signal transducer and activator of transcription 5B [KO:K11224]
            12443  Ccnd1; cyclin D1 [KO:K04503]
            12567  Cdk4; cyclin-dependent kinase 4 [KO:K02089] [EC:2.7.11.22]
            13653  Egr1; early growth response 1 [KO:K09203]
COMPOUND    C00031  D-Glucose
            C00076  Calcium cation
            C00165  Diacylglycerol
            C00195  N-Acylsphingosine
            C01245  D-myo-Inositol 1,4,5-trisphosphate
            C21011  [Protein]-N(epsilon)-(carboxymethyl)lysine
            C21012  [Protein]-N(epsilon)-(carboxyethyl)lysine
            C21013  [Protein]-pyrraline
            C21014  [Protein]-pentosidine
REFERENCE   PMID:21261520
  AUTHORS   Kanwar YS, Sun L, Xie P, Liu FY, Chen S
  TITLE     A glimpse of various pathogenetic mechanisms of diabetic nephropathy.
  JOURNAL   Annu Rev Pathol 6:395-423 (2011)
            DOI:10.1146/annurev.pathol.4.110807.092150
REFERENCE   PMID:21111800
  AUTHORS   Yamagishi S
  TITLE     Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
  JOURNAL   Exp Gerontol 46:217-24 (2011)
            DOI:10.1016/j.exger.2010.11.007
REFERENCE   PMID:23961320
  AUTHORS   Roy B
  TITLE     Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures.
  JOURNAL   World J Diabetes 4:101-13 (2013)
            DOI:10.4239/wjd.v4.i4.101
REFERENCE   PMID:22558488
  AUTHORS   Hegab Z, Gibbons S, Neyses L, Mamas MA
  TITLE     Role of advanced glycation end products in cardiovascular disease.
  JOURNAL   World J Cardiol 4:90-102 (2012)
            DOI:10.4330/wjc.v4.i4.90
REFERENCE   PMID:19404313
  AUTHORS   Calcutt NA, Cooper ME, Kern TS, Schmidt AM
  TITLE     Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials.
  JOURNAL   Nat Rev Drug Discov 8:417-29 (2009)
            DOI:10.1038/nrd2476
REFERENCE   PMID:11180401
  AUTHORS   Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY
  TITLE     Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells.
  JOURNAL   J Cell Biochem 81:102-13 (2001)
            DOI:10.1002/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y
REFERENCE   PMID:21680901
  AUTHORS   Meloche J, Paulin R, Courboulin A, Lambert C, Barrier M, Bonnet P, Bisserier M, Roy M, Sussman MA, Agharazii M, Bonnet S
  TITLE     RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes.
  JOURNAL   Arterioscler Thromb Vasc Biol 31:2114-24 (2011)
            DOI:10.1161/ATVBAHA.111.230573
REFERENCE   PMID:11684565
  AUTHORS   Guh JY, Huang JS, Chen HC, Hung WC, Lai YH, Chuang LY
  TITLE     Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1.
  JOURNAL   Am J Kidney Dis 38:1096-104 (2001)
            DOI:10.1053/ajkd.2001.28616
REFERENCE   PMID:16894049
  AUTHORS   Goldin A, Beckman JA, Schmidt AM, Creager MA
  TITLE     Advanced glycation end products: sparking the development of diabetic vascular injury.
  JOURNAL   Circulation 114:597-605 (2006)
            DOI:10.1161/CIRCULATIONAHA.106.621854
REFERENCE   PMID:21590515
  AUTHORS   Zong H, Ward M, Stitt AW
  TITLE     AGEs, RAGE, and diabetic retinopathy.
  JOURNAL   Curr Diab Rep 11:244-52 (2011)
            DOI:10.1007/s11892-011-0198-7
REFERENCE   PMID:21440603
  AUTHORS   Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S
  TITLE     Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
  JOURNAL   Biochim Biophys Acta 1820:663-71 (2012)
            DOI:10.1016/j.bbagen.2011.03.014
REFERENCE   PMID:23776698
  AUTHORS   Shi L, Yu X, Yang H, Wu X
  TITLE     Advanced glycation end products induce human corneal epithelial cells apoptosis through generation of reactive oxygen species and activation of JNK and p38 MAPK pathways.
  JOURNAL   PLoS One 8:e66781 (2013)
            DOI:10.1371/journal.pone.0066781
REFERENCE   PMID:17005604
  AUTHORS   Alikhani M, Maclellan CM, Raptis M, Vora S, Trackman PC, Graves DT
  TITLE     Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor.
  JOURNAL   Am J Physiol Cell Physiol 292:C850-6 (2007)
            DOI:10.1152/ajpcell.00356.2006
REFERENCE   PMID:20300563
  AUTHORS   Alikhani M, Roy S, Graves DT
  TITLE     FOXO1 plays an essential role in apoptosis of retinal pericytes.
  JOURNAL   Mol Vis 16:408-15 (2010)
REFERENCE   PMID:20470857
  AUTHORS   Sheikpranbabu S, Haribalaganesh R, Lee KJ, Gurunathan S
  TITLE     Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability.
  JOURNAL   Biochimie 92:1040-51 (2010)
            DOI:10.1016/j.biochi.2010.05.004
REFERENCE   PMID:18922799
  AUTHORS   Hudson BI, Kalea AZ, Del Mar Arriero M, Harja E, Boulanger E, D'Agati V, Schmidt AM
  TITLE     Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42.
  JOURNAL   J Biol Chem 283:34457-68 (2008)
            DOI:10.1074/jbc.M801465200
REFERENCE   PMID:11375353
  AUTHORS   Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L
  TITLE     Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion.
  JOURNAL   Diabetes 50:1495-504 (2001)
            DOI:10.2337/diabetes.50.6.1495
REFERENCE   PMID:12709399
  AUTHORS   Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY
  TITLE     Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease.
  JOURNAL   FASEB J 18:176-8 (2004)
            DOI:10.1096/fj.02-1117fje
REFERENCE   PMID:18323529
  AUTHORS   Chang JS, Wendt T, Qu W, Kong L, Zou YS, Schmidt AM, Yan SF
  TITLE     Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products.
  JOURNAL   Circ Res 102:905-13 (2008)
            DOI:10.1161/CIRCRESAHA.107.165308
REFERENCE   PMID:15569303
  AUTHORS   Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S
  TITLE     AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction.
  JOURNAL   Kidney Int 66:2137-47 (2004)
            DOI:10.1111/j.1523-1755.2004.66004.x
REL_PATHWAY mmu04010  MAPK signaling pathway
            mmu04020  Calcium signaling pathway
            mmu04110  Cell cycle
            mmu04151  PI3K-Akt signaling pathway
            mmu04350  TGF-beta signaling pathway
            mmu04614  Renin-angiotensin system
            mmu04630  JAK-STAT signaling pathway
KO_PATHWAY  ko04933
///
